Royal Bank of Canada
CNTX icon

Royal Bank of Canada’s Context Therapeutics CNTX Stock Holding History

Royal Bank of Canada’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-100
Closed – – 7283
2022
Q3 		$0 Hold
100
– – ﹤0.01% 7490
2022
Q2 		$0 Hold
100
– – ﹤0.01% 7404
2022
Q1 		$0 Hold
100
– – ﹤0.01% 7771
2021
Q4 		$0 Buy
+100
New +$498 ﹤0.01% 7673

Other funds holding CNTX

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
S
swisspartners Vaduz, Liechtenstein $78.4M AUM 9.82% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada's CNTX Position: Q4 2022 in Review

Royal Bank of Canada sold out of Context Therapeutics (CNTX) in Q4 2022, closing a stake of 100 shares.

Royal Bank of Canada first reported a position in CNTX in Q4 2021 and held it in 4 quarters. The position peaked at $0 in Q3 2022. 24 funds tracked by Wall St. Rank hold CNTX as of Q4 2022.

  • Royal Bank of Canada reported no remaining Context Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Royal Bank of Canada sold 100 Context Therapeutics shares in Q4 2022.
  • Royal Bank of Canada first reported a position in Context Therapeutics in Q4 2021 and held it in 4 quarters.
  • Royal Bank of Canada's Context Therapeutics position peaked at $0 in Q3 2022.
  • 24 funds tracked by Wall St. Rank held Context Therapeutics as of Q4 2022.

Based on Royal Bank of Canada's 13F filing for Q4 2022, filed 14 Feb 2023.